Information Provided By: 
Fly News Breaks for February 25, 2020
TBPH
Feb 25, 2020 | 05:25 EDT
Piper Sandler analyst Tyler Van Buren lowered the firm's price target on Theravance Biopharma to $35 from $40 and keeps an Overweight rating on the shares. Trelegy posted a good quarter and the launch could further inflect with an approval in asthma mid-year, Van Buren tells investors in a research note. However, the analyst adds that Theravance's "major value-creating events" in inflammatory bowel disease and neurogenic orthostatic hypotension are not expected until year-end.
News For TBPH From the Last 2 Days
There are no results for your query TBPH
